Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Pietro IaffaldanoGiuseppe LucisanoAlessia ManniDamiano PaolicelliFrancesco PattiMarco CapobiancoVincenzo Brescia MorraPatrizia SolaIlaria PesciGiacomo LusGiovanna De LucaAlessandra LugaresiPaola CavallaSara MontepietraGiorgia Teresa ManiscalcoFranco GranellaPaolo RagoneseMarika VianelloLaura BrambillaRocco TotaroSimona ToscanoSimona MalucchiMaria PetraccaLucia MoiolaDiana FerraroVito LeporePaola MosconiMichela PonzioGioacchino TedeschiGiancarlo ComiMario Alberto BattagliaMassimo FilippiMaria Pia AmatoMaria Trojanonull nullPublished in: Neurology(R) neuroimmunology & neuroinflammation (2022)
This study provides Class III evidence that among patients with MS, younger age, being female individuals, having more comorbidities, receiving natalizumab, undergoing an escalating treatment strategy, or receiving treatment at a hospital were associated with being infected with COVID-19. Among patients with MS who were infected with COVID-19, a severe course was associated with increasing age and having a progressive form of MS, whereas not being on treatment or receiving an interferon beta agent was protective.